$9.28−0.23 (−2.37%)
At close: Nov 17, 2026, 4:00 PM ET· Nasdaq · USD
Cullinan Therapeutics (CGEM) Income Statement
Is this a real, growing, cash-generative business, or a story propped up by accounting?
Sources Company filings FilingsHow we compute thisNot investment advice
25 figures withheld by our checks. Each blank figure names its reason.
Business engineChoppy: revenue history is too short to read a growth trend (through FY21), net margin −356.3%. Worth your attention in FY25: Share count (+38.6%). Visible in the receipts below.
The lines that matter · FY21–FY25
Revenue ($M)—
0.0
no value for 1 of 5 yearsCAGR —
Net income ($M)▼31.4%
−219.9
no value for 1 of 5 yearsCAGR —
Free cash flow ($M)▼21.0%
−175.8
FY21→FY25CAGR —
What the receipts whisper · what a headline number hides
Share count
+38.6%
43.1mn → 59.7mn diluted shares since FY21. Rising share count dilutes EPS. Growth must outrun it.
What the income statement says · FY21–FY25
Where every revenue dollar goes · FY25 ($M)
Margin trend · direction beats level Gross Operating Net
The receipt · income statement · FY21–FY25 USD thousands except per-share & ratios · hover a line for its definition
USD thousands except per-share & ratios
| Line item | TTM † | FY25 | FY24 | FY23 | FY22 | FY21 | YoY | CAGR 21→25 |
|---|---|---|---|---|---|---|---|---|
| Revenue & profitability | ||||||||
Revenue | — | 0.0 | 0.0 | 0.0 | —A | 18,943.0 | — | — |
Cost of revenue | — | 0.0 | 0.0 | 0.0 | —A | 0.0 | — | — |
Gross profit | — | 0.0 | 0.0 | 0.0 | —A | 18,943.0 | — | — |
Research & development | 169,674.0 | 187,402.0 | 142,903.0 | 148,156.0 | —A | 57,751.0 | ▲31.1% | — |
Selling, general & admin | 49,136.0 | 54,246.0 | 54,016.0 | 42,493.0 | —A | 29,146.0 | ▲0.4% | — |
Total operating expenses | 218,810.0 | 241,648.0 | 196,919.0 | 190,649.0 | —A | 86,897.0 | ▲22.7% | — |
Operating incomefeeds ROC rank | −218,810.0 | −241,648.0 | −196,919.0 | −191,089.0 | —A | −67,954.0 | ▼22.7% | — |
Other income, net | 15,344.0 | 21,769.0 | 29,461.0 | 21,866.0 | —A | 469.0 | — | — |
Pretax income | −203,466.0 | −219,879.0 | −167,458.0 | −169,223.0 | —A | −67,485.0 | ▼31.3% | — |
Income tax | — | 0.0 | 117.0 | −14,122.0 | —A | — | — | — |
Net incomePiotroski ROA ✕feeds Buffett Quality owner earnings | −203,466.0 | −219,879.0 | −167,383.0 | −153,162.0 | —A | −67,485.0 | ▼31.4% | — |
| Per share | ||||||||
Diluted EPSbuyback-sensitive | —A | —A | —A | —A | —A | —A | — | — |
Diluted shares (mn) | 64.60 | 59.70 | 54.42 | 42.16 | —A | 43.08 | ▲9.7% | — |
| Margins | ||||||||
Gross margin | — | — | — | — | —A | 100.0% | — | — |
Operating margin | — | — | — | — | —A | −358.7% | — | — |
Net margin | — | — | — | — | —A | −356.3% | — | — |
† TTM = trailing four quarters through 2026-09-30.A Withheld by our checks.
1 more year of statements and CSV export are on Premium.Premium · $119/yr · 7-day trial · cancel anytimeUnlock with Premium →
These lines feed the tenet checklists: see which gates passTenets →Margins & returns continue as sector-ranked ratiosStatistics →
Annual report filed 2026-03-10 · view filings on SEC EDGAR ↗ · reported currency USD · as-filed figures may be later restated.
Statements normalized in our fundamentals DB · Not investment advice.
Statements normalized in our fundamentals DB · Not investment advice.
Annual and quarterly statements as filed, normalized into one comparable shape · Not investment advice.

